The Checkpoint Inhibitors for Treating Cancer Market Report 2021-2031: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
New Products/Therapy Launch Are Gaining Tractions in the Global Market
To distinguish their product offerings, new entrants into the oncology industry may use a variety of strategies. One strategy is to be first-in-class with a novel mechanism of action (MOA); another is to focus on an indication with a strong unmet need, thus providing a valuable new therapeutic choice for patients with few choices.
Increasing Support from FDA in the Approval Procedures
Currently, the FDA has licenced two anti-PD-1 antibodies: pembrolizumab and nivolumab. These medications, such as ipilimumab, were initially approved to treat advanced-stage melanomas but have since been approved to treat a variety of cancers. The third group of FDA-approved ICIs is antibodies against PD-L1. Urothelial carcinoma, non-small cell lung cancer (NSCLC), and Merkel cell carcinoma are treated with three anti-PD-L1 antibodies: atezolizumab, durvalumab, and avelumab. Anti-PD-1 and anti-PD-L1 antibodies have outperformed anti-CTLA-4 antibodies in clinical trials due to a combination of superior clinical efficacy and tolerability
What Are These Questions You Should Ask Before Buying A Market Research Report?
• How is the checkpoint inhibitors for treating cancer market evolving?
• What is driving and restraining the checkpoint inhibitors for treating cancer market?
• How will each checkpoint inhibitors for treating cancer submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2031?
• How will the market shares for each checkpoint inhibitors for treating cancer submarket develop from 2021 to 2031?
• What will be the main driver for the overall market from 2021 to 2031?
• Will leading checkpoint inhibitors for treating cancer markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2031 and which geographical region will lead the market in 2031?
• Who are the leading players and what are their prospects over the forecast period?
• What are the checkpoint inhibitors for treating cancer projects for these leading companies?
• How will the industry evolve during the period between 2020 and 2031?What are the implication of checkpoint inhibitors for treating cancer projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the checkpoint inhibitors for treating cancer market?
• Where is the checkpoint inhibitors for treating cancer market heading? And how can you ensure you are at the forefront of the market?
• What can be the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path? C-suite?
You need to discover how this will impact the checkpoint inhibitors for treating cancer market today, and over the next 10 years:
• Our 612-page report provides 447 tables and 448 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• Contains in-depth analyse of global, regional and national sales and growth
• Highlights for you the key successful trends, changes and revenue projections made by your competitors
This report tells you TODAY how the checkpoint inhibitors for treating cancer market will develop in the next 10 years, and in-line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.
This report includes data analysis and invaluable insight into how COVID-19 will affect your industry. Access this report today.
Forecasts to 2031 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising checkpoint inhibitors for treating cancer prices and recent developments.
This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, V, L, W and U are discussed in this report.
Global Checkpoint Inhibitors for Treating Cancer Market (COVID Impact Analysis) by Category
• PD1 Inhibitors
• PD-L1 Inhibitors
• CTLA-4 Inhibitors
• Cytokines Targets
• Immuno Adjuvants
• Immunomodulators
Global Checkpoint Inhibitors for Treating Cancer Market (COVID Impact Analysis) by PD1 Inhibitors
• Pembrolizumab (Keytruda)
• Nivolumab (Opdivo)
• Cemiplimab (Libtayo)
Global Checkpoint Inhibitors for Treating Cancer Market (COVID Impact Analysis) by PD-L1 Inhibitors
• Atezolizumab (Tecentriq)
• Avelumab (Bavencio)
• Durvalumab (Imfinzi)
Global Checkpoint Inhibitors for Treating Cancer Market (COVID Impact Analysis) by CTLA-4 Inhibitors
• Ipilimumab (Yervoy)
Global Checkpoint Inhibitors for Treating Cancer Market (COVID Impact Analysis) by Immuno Adjuvants
• Imiquimod
• Poly ICLC (Hiltonol)
Global Checkpoint Inhibitors for Treating Cancer Market (COVID Impact Analysis) by Immunomodulators
• Pexidartinib (Turalio)
Global Checkpoint Inhibitors for Treating Cancer Market (COVID Impact Analysis) by Cytokines Targets
• Aldesleukin
• GM-CSF
• Interferon Alfa-2a
• Interferon alfa-2b (Intron A)
• Peginterferon alfa-2b (Sylatron/PEG-Intron)
Global Checkpoint Inhibitors for Treating Cancer Market (COVID Impact Analysis) by Application
• Lung Cancer Treatment
• Renal Cancer Treatment
• Blood Cancer Treatment
• Bladder Cancer Treatment
• Other Application
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 4 regional and 20 leading national markets:
• North America Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 Market Outlook
• U.S. Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 Market Forecast & COVID Impact Analysis
• Canada Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 Market Forecast & COVID Impact Analysis
• Mexico Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 Market Forecast & COVID Impact Analysis
• Europe Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 Market Outlook
• Germany Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 Market Forecast & COVID Impact Analysis
• Spain Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 Market Forecast & COVID Impact Analysis
• United Kingdom Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 Market Forecast & COVID Impact Analysis
• France Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 Market Forecast & COVID Impact Analysis
• Italy Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 Market Forecast & COVID Impact Analysis
• Rest of Europe Market Forecast & COVID Impact Analysis
• Asia Pacific Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 Market Outlook
• China Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 Market Forecast & COVID Impact Analysis
• Japan Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 Market Forecast & COVID Impact Analysis
• India Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 Market Forecast & COVID Impact Analysis
• Australia Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 Market Forecast & COVID Impact Analysis
• South Korea Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 Market Forecast & COVID Impact Analysis
• Rest of Asia Pacific Market Forecast & COVID Impact Analysis
• LAMEA Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 Market Outlook
• Brazil Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 Market Forecast & COVID Impact Analysis
• Turkey Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 Market Forecast & COVID Impact Analysis
• Saudi Arabia Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 Market Forecast & COVID Impact Analysis
• South Africa Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 Market Forecast & COVID Impact Analysis
• UAE Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 Market Forecast & COVID Impact Analysis
• Rest of Latin America, Middle East and Africa
The report also includes profiles and for some of the leading companies in the Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031, with a focus on this segment of these companies’ operations.
Leading companies and the potential for market growth
• A Seagen Inc.,
• Agenus Inc. (Agenus)
• Agilent Technologies, Inc.
• AbbVie Inc. (AbbVie)
• Xencor, Inc.
• Ono Pharmaceutical Co., Ltd.
• Sanofi SA
• Eli Lilly and Company
• Novartis AG
• Pfizer Inc. (Pfizer)
• Roche Holding AG (Roche)
• Merck & Co., Inc.
• Incyte Corporation
• Regeneron Pharmaceuticals, Inc.
• Amgen Inc.
• Bristol-Myers Squibb Company
• Clovis Oncology, Inc.
• Heptares Therapeutics Ltd.
Overall world revenue for Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 in terms of value the market will surpass US$xx million in 2021, our work calculates. We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How the Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 Market report helps you?
In summary, our 610+ page report provides you with the following knowledge:
• Revenue forecasts to 2031 for 4 regional and 20 key national markets – See forecasts for the Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 market in North America, Europe, Asia-Pacific and LAMEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market– including company profiles for 20 of the major companies involved in the Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 Market.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else
With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Our study is for everybody needing commercial analyses for the Checkpoint Inhibitors for Treating Cancer Market, 2021 to 2031 Market and leading companies. You will find data, trends and predictions.
'
1. Report Overview
1.1 Introduction to Checkpoint Inhibitors Market
1.2 Global Checkpoint Inhibitors Market Overview
1.3 What are the Objectives of this Report?
1.4 What is the Scope of the Report?
1.5 Checkpoint Inhibitors Market Definition
1.6 Why You Should Read This Report
1.7 What This Report Delivers
1.8 Key Questions Answered by This Analytical Report Include:
1.9 Who is This Report for?
1.10 Research Methodology
1.10.1 Primary Research
1.10.2 Secondary Research
1.10.3 Market Evaluation & Forecasting Methodology
1.11 Frequently Asked Questions (FAQs)
1.12 Associated Reports
1.13 About
2 Executive Summary
3 Checkpoint Inhibitors Industry Structure
3.1 Overview
3.1.1 Inhibitory Immune Checkpoint Targets
3.1.2 Immunometabolic Modulatory Targets
3.1.3 CAR-T Cells
4 Global Market Dynamics
4.1 Current Trends in the Global Market
4.2 Market Driving Factors
4.2.1 Peripheral Immune Responses Are Critical in Achieving Favourable Clinical Outcomes
4.2.2 New Products/Therapy Launch Are Gaining Tractions in the Global Market
4.2.3 Increasing Support from FDA in the Approval Procedures
4.3 Market Restraining Factors
4.3.1 Most Patients and Cancers Do Not Respond to Checkpoint Inhibitor Therapies
4.3.2 Immune-Related Adverse Events Occurred, Restraining Further Research
4.3.3 An Increased Risk of Thromboembolism
4.4 Opportunities in the Global Market
4.4.1 Unprecedented Advances in Cancer Immunotherapy
4.4.2 Unmet Medical Needs
4.4.3 New Combinations Therapies Creating New Opportunities
4.5 Challenges in the Global Market
4.5.1 Lack of Understanding in Regards to Checkpoint Inhibitors Mechanisms
4.5.2 Resistance to Immune Checkpoint Inhibitors
4.5.3 Whether irAE Presentation Correlates with ICI efficacy is a Challenge
5 Global Checkpoint Inhibitors Market Analysis
5.1 Global Market Outlook
5.2 Global Market Size Estimation and Forecast
5.2.1 Pre-COVID-19 Market Scenario
5.2.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
6 Global Market Breakdown by Category
6.1 Segment Overview
6.1.1 PD-1 inhibitor:
6.1.2 PD-L1 Inhibitors:
6.1.3 CTLA-4 Inhibitors:
6.1.4 Cytokines Targets:
6.1.5 Immuno Adjuvants
6.1.6 Immunomodulators
6.1.7 Pre-COVID-19 Market Scenario
6.1.8 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
7 Global Market Breakdown by PD1 Inhibitors
7.1 Segment Overview
7.1.1 Introduction to PD-1/PD-L1 Agents
7.1.2 Pembrolizumab (Keytruda), Merck & Co.
7.1.3 Nivolumab (Opdivo), BMS
7.1.4 Atezolizumab (Tecentriq), Genentech
7.1.5 Cemiplimab (Libtayo), Regeneron/Sanofi
7.1.6 Pre-COVID-19 Market Scenario
7.1.7 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
7.2 Global Market Breakdown by PD-L1 Inhibitors
7.2.1 Avelumab (Bavencio), Merck KGaA/Pfizer
7.2.2 Durvalumab (Imfinzi), AstraZeneca
7.2.3 Pre-COVID-19 Market Scenario
7.2.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
8 Global Market Breakdown by CTLA-4 Inhibitors
8.1 Segment Overview
8.1.1 Pre-COVID-19 Market Scenario
8.1.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
9 Global Market Breakdown by Cytokines Target
9.1 Segment Overview
9.1.1 Pre-COVID-19 Market Scenario
9.1.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
10 Global Market Breakdown by Immuno Adjuvants
10.1 Segment Overview
10.1.1 Pre-COVID-19 Market Scenario
10.1.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
11 Global Market Breakdown by Immuno Modulators
11.1 Segment Overview
11.2 Pre-COVID-19 Market Scenario
11.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
12 Global Market Breakdown by Application
12.1 Segment Overview
12.1.1 Lung Cancer Treatment
12.1.2 Renal Cancer Treatment
12.1.3 Blood Cancer Treatment
12.1.4 Bladder Cancer Treatment
12.2 Pre-COVID-19 Market Scenario
12.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
13 Global Checkpoint Inhibitors Market by Region
13.1 Regional Market Size Estimation and Forecast
13.1.1 Pre-COVID-19 Market Scenario
13.1.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14 North America Checkpoint Inhibitors Market Analysis
14.1 North America Market Outlook
14.2 North America Market Size Estimation and Forecast
14.2.1 Pre-COVID-19 Market Scenario
14.2.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.3 Country Market Size Estimation and Forecast
14.3.1 Pre-COVID-19 Market Scenario
14.3.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.4 North America Market Breakdown by Category
14.4.1 Pre-COVID-19 Market Scenario
14.4.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.5 North America Market Breakdown by PD-1 Inhibitors
14.5.1 Pre-COVID-19 Market Scenario
14.5.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.6 North America Market Breakdown by PD-L1 Inhibitors
14.6.1 Pre-COVID-19 Market Scenario
14.6.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.7 North America Market Breakdown by CTLA-4 Inhibitors
14.7.1 Pre-COVID-19 Market Scenario
14.7.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.8 North America Market Breakdown by Cytokines Target
14.8.1 Pre-COVID-19 Market Scenario
14.8.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.9 North America Market Breakdown by Application
14.9.1 Pre-COVID-19 Market Scenario
14.9.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.10 North America Market Breakdown by Immuno Adjuvants
14.10.1 Pre-COVID-19 Market Scenario
14.10.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.11 North America Market Breakdown by Immunomodulators
14.11.1 Pre-COVID-19 Market Scenario
14.11.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.12 US Checkpoint Inhibitors Market Analysis
14.12.1 Clinical Use of Checkpoint Inhibitors is Growing Rapidly in the US
14.12.2 Acceptance of Checkpoint Inhibitors for Treating Cancer
14.12.3 Pre-COVID-19 Market Scenario
14.12.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.13 Canada Checkpoint Inhibitors Market Analysis
14.13.1 Patients Response to Checkpoint Inhibitor Therapies is Low in the Country
14.13.2 Canada Market Is Expected to Grow at a Steady Pase
14.13.3 Pre-COVID-19 Market Scenario
14.13.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
14.14 Mexico Checkpoint Inhibitors Market Analysis
14.14.1 Mexico Is One of the Research Centres for Checkpoint Inhibitors.
14.14.2 PD-1/PD-L1 Inhibitors Continue to Change the Cancer Treatment Landscape in the Country
14.14.3 Pre-COVID-19 Market Scenario
14.14.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15 Europe Checkpoint Inhibitors Market Analysis
15.1 Europe Market Outlook
15.2 Europe Market Size Estimation and Forecast
15.2.1 Pre-COVID-19 Market Scenario
15.2.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.3 Europe Market Size Estimation and Forecast by Region
15.3.1 Pre-COVID-19 Market Scenario
15.3.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.4 Europe Market Size Estimation and Forecast by Category
15.4.1 Pre-COVID-19 Market Scenario
15.4.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.5 Europe Market Size Estimation and Forecast by PD1 Inhibitors
15.5.1 Pre-COVID-19 Market Scenario
15.5.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.6 Europe Market Size Estimation and Forecast by PD-L1 Inhibitors
15.6.1 Pre-COVID-19 Market Scenario
15.6.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.7 Europe Market Size Estimation and Forecast by CTLA-4 Inhibitors:
15.7.1 Pre-COVID-19 Market Scenario
15.7.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.8 Europe Market Size Estimation and Forecast by Cytokines Targets:
15.8.1 Pre-COVID-19 Market Scenario
15.8.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.9 Europe Market Size Estimation and Forecast by Application
15.9.1 Pre-COVID-19 Market Scenario
15.9.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.10 Europe Market Size Estimation and Forecast by Immuno Adjuvants:
15.10.1 Pre-COVID-19 Market Scenario
15.10.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.11 Europe Market Size Estimation and Forecast by Immonumodulators
15.11.1 Pre-COVID-19 Market Scenario
15.11.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.12 Germany Checkpoint Inhibitors Market Analysis
15.12.1 German Companies Pursuing Bispecific for The Next Generation of Checkpoint Inhibitors
15.12.2 Companies Are Trying All Kinds of Combinations to Make Checkpoint Inhibitors Work for More People
15.12.3 Pre-COVID-19 Market Scenario
15.12.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.13 UK Checkpoint Inhibitors Market Analysis
15.13.1 High Tumour Mutation Burden Predicts Response to Immune Checkpoint Blockade for Some Cancer Types
15.13.2 UK Checkpoint Inhibitors Market to Grow at a Decent Rate
15.13.3 Pre-COVID-19 Market Scenario
15.13.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.14 France Checkpoint Inhibitors Market Analysis
15.14.1 Checkpoint Inhibitors Have Proven to Be Powerful Anti-Tumour Drugs
15.14.2 French Companies Facing Failures in Checkpoint Inhibitors Research
15.14.3 Pre-COVID-19 Market Scenario
15.14.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.15 Italy Checkpoint Inhibitors Market Analysis
15.15.1 Immunotherapy, And More Recently as Immuno-Oncology Therapies Are in Demand in The Country
15.15.2 Strong Pharmacovigilance Infrastructure in The Country.
15.15.3 Pre-COVID-19 Market Scenario
15.15.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.16 Spain Checkpoint Inhibitors Market Analysis
15.16.1 Prostate Cancer Is the Third Most Frequent Neoplasms in Spain
15.16.2 Therapeutic Strategies to Enhance Immune-Responsiveness in Prostate Cancer
15.16.3 Pre-COVID-19 Market Scenario
15.16.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
15.17 Rest of Europe Checkpoint Inhibitors Market Analysis
15.17.1 Pre-COVID-19 Market Scenario
15.17.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16 Asia-Pacific Checkpoint Inhibitors Market Analysis
16.1 Asia-Pacific Market Outlook
16.1.1 Chinese Checkpoint Inhibitors Are Poised to Change Global Market Dynamics
16.2 Asia-Pacific Market Size Estimation and Forecast
16.2.1 Pre-COVID-19 Market Scenario
16.2.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16.3 Country Market Size Estimation and Forecast
16.3.1 Pre-COVID-19 Market Scenario
16.3.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16.4 Asia-Pacific Market Breakdown by Category
16.4.1 Pre-COVID-19 Market Scenario
16.4.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16.5 Asia-Pacific Market Breakdown by PD-1 Inhibitors
16.5.1 Pre-COVID-19 Market Scenario
16.5.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16.6 Asia-Pacific Market Breakdown by PD-L1 Inhibitors
16.6.1 Pre-COVID-19 Market Scenario
16.6.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16.7 Asia-Pacific Market Breakdown by CTLA-4 Inhibitors
16.7.1 Pre-COVID-19 Market Scenario
16.7.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16.8 Asia-Pacific Market Breakdown by Cytokines Targets
16.8.1 Pre-COVID-19 Market Scenario
16.8.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16.9 Asia-Pacific Market Breakdown by Application
16.9.1 Pre-COVID-19 Market Scenario
16.9.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16.10 Asia-Pacific Market Breakdown by Immuno Adjuvants
16.10.1 Pre-COVID-19 Market Scenario
16.10.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16.11 Asia-Pacific Market Breakdown by Immonumodulators
16.11.1 Pre-COVID-19 Market Scenario
16.11.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16.12 China Checkpoint Inhibitors Market Analysis
16.12.1 China Supporting Local ICI Companies
16.12.2 International ICI Brands Seeking Market Access in China
16.12.3 Pre-COVID-19 Market Scenario
16.12.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16.13 India Checkpoint Inhibitors Market Analysis
16.13.1 Increasing Breast Cancer Patients in India
16.13.2 Surgery Is the Mainstay of Treatment of the Early Stages of Breast Cancer in The Country
16.13.3 Upcoming Other Efficient Treatments such as Checkpoint Inhibitors in the Country
16.13.4 Pre-COVID-19 Market Scenario
16.13.5 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16.14 Japan Checkpoint Inhibitors Market Analysis
16.14.1 Use of Neoadjuvant Trials to Drive Progress in Head and Neck Cancer Immunotherapy
16.14.2 Country is Focusing on Various Application Areas of Checkpoint Inhibitors
16.14.3 Pre-COVID-19 Market Scenario
16.14.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16.15 South Korea Checkpoint Inhibitors Market Analysis
16.15.1 More Emphasis Given On Radiation & Immunotherapy as Compared to CHI
16.15.2 The Role of ICIs in Earlier Stages of Disease Is Unclear
16.15.3 Pre-COVID-19 Market Scenario
16.15.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16.16 Australia Checkpoint Inhibitors Market Analysis
16.16.1 Australia Heading the Research on Checkpoint Inhibitors
16.16.2 Triebel spun out the Australian-European immunotherapy company
16.16.3 Pre-COVID-19 Market Scenario
16.16.4 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
16.17 Rest of Asia-Pacific Checkpoint Inhibitors Market Analysis
16.17.1 Pre-COVID-19 Market Scenario
16.17.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
17 LAMEA Checkpoint Inhibitors Market Analysis
17.1 LAMEA Market Outlook
17.2 LAMEA Market Size Estimation and Forecast
17.2.1 Pre-COVID-19 Market Scenario
17.2.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
17.3 Country Market Size Estimation and Forecast
17.3.1 Pre-COVID-19 Market Scenario
17.3.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
17.4 LAMEA Market Breakdown by Category
17.4.1 Pre-COVID-19 Market Scenario
17.4.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
17.5 LAMEA Market Breakdown by PD-1 Inhibitors:
17.5.1 Pre-COVID-19 Market Scenario
17.5.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
17.6 LAMEA Market Breakdown by PD-L1 Inhibitors:
17.6.1 Pre-COVID-19 Market Scenario
17.6.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
17.7 LAMEA Market Breakdown by CTLA-4 Inhibitors:
17.7.1 Pre-COVID-19 Market Scenario
17.7.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
17.8 LAMEA Market Breakdown by Cytokines Targets:
17.8.1 Pre-COVID-19 Market Scenario
17.8.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
17.9 LAMEA Market Breakdown by Application:
17.9.1 Pre-COVID-19 Market Scenario
17.9.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
17.10 LAMEA Market Breakdown by Immuno Adjuvants:
17.10.1 Pre-COVID-19 Market Scenario
17.10.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
17.11 LAMEA Market Breakdown by Immunomodulators:
17.11.1 Pre-COVID-19 Market Scenario
17.11.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
17.12 Brazil Checkpoint Inhibitors Market Analysis
17.12.1 Country Adopting Therapeutic Strategies to Enhance Immune-Responsiveness in Prostate Cancer
17.12.2 Pre-COVID-19 Market Scenario
17.12.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
17.13 South Africa Checkpoint Inhibitors Market Analysis
17.13.1 Checkpoint Inhibitors Are Also Being Investigated in Combination with Chemotherapy
17.13.2 Pre-COVID-19 Market Scenario
17.13.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
17.14 Saudi Arabia Checkpoint Inhibitors Market Analysis
17.14.1 Increasing Importance of Immune Checkpoint Inhibitor Therapy
17.14.2 Pre-COVID-19 Market Scenario
17.14.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
17.15 Turkey Checkpoint Inhibitors Market Analysis
17.15.1 Immune Checkpoint Inhibitor Research Under Trials
17.15.2 Pre-COVID-19 Market Scenario
17.15.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
17.16 UAE Checkpoint Inhibitors Market Analysis
17.16.1 Negative Side of ICI Reported in UAE
17.16.2 Pre-COVID-19 Market Scenario
17.16.3 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
17.17 Rest of LAMEA Checkpoint Inhibitors Market Analysis
17.17.1 Pre-COVID-19 Market Scenario
17.17.2 Post-COVID-19 Market Scenarios (V, W, U, L-Shaped Recovery Analysis)
18 Leading Company Profiles
18.1 Competitive Landscape
18.1.1 Collaborations and Partnerships in the Global Market
18.2 Seagen Inc.
18.2.1 Company Snapshot
18.2.2 Company Overview
18.2.3 Company Financial Profile
18.2.4 Company Product Benchmarking
18.2.5 Company Recent Developments
18.3 AGENUS INC.
18.3.1 Company Snapshot
18.3.2 Company Overview
18.3.3 Company Financial Profile
18.3.4 Company Product Benchmarking
18.3.5 Company Recent Developments
18.4 Agilent Technologies
18.4.1 Company Snapshot
18.4.2 Company Overview
18.4.3 Company Financial Profile
18.4.4 Company Product Benchmarking
18.4.5 Company Recent Developments
18.5 AbbVie Inc.
18.5.1 Company Snapshot
18.5.2 Company Overview
18.5.3 Company Financial Profile
18.5.4 Company Product Benchmarking
18.5.5 Company Recent Developments
18.6 xencor
18.6.1 Company Snapshot
18.6.2 Company Overview
18.6.3 Company Financial Profile
18.6.4 Company Product Benchmarking
18.6.5 Company Recent Developments
18.7 Ono pharmaceutical
18.7.1 Company Snapshot
18.7.2 Company Overview
18.7.3 Company Financial Profile
18.7.4 Company Product Benchmarking
18.7.5 Company Recent Developments
18.8 Sanofi SA
18.8.1 Company Snapshot
18.8.2 Company Overview
18.8.3 Company Financial Profile
18.8.4 Company Product Benchmarking
18.8.5 Company Recent Developments
18.9 Eli Lilly and Co
18.9.1 Company Snapshot
18.9.2 Company Overview
18.9.3 Company Financial Profile
18.9.4 Company Product Benchmarking
18.9.5 Company Recent Developments
18.10 Kyowa Hakko Kirin
18.10.1 Company Snapshot
18.10.2 Company Overview
18.10.3 Company Financial Profile
18.10.4 Company Product Benchmarking
18.10.5 Company Recent Developments
18.11 Novartis
18.11.1 Company Snapshot
18.11.2 Company Overview
18.11.3 Company Financial Profile
18.11.4 Company Product Benchmarking
18.11.5 Company Recent Developments
18.12 Pfizer Inc.
18.12.1 Company Snapshot
18.12.2 Company Overview
18.12.3 Company Financial Profile
18.12.4 Company Product Benchmarking
18.12.5 Company Recent Developments
18.13 Roche
18.13.1 Company Snapshot
18.13.2 Company Overview
18.13.3 Company Financial Profile
18.13.4 Company Product Benchmarking
18.13.5 Company Recent Developments
18.14 Merck & Co.
18.14.1 Company Snapshot
18.14.2 Company Overview
18.14.3 Company Financial Profile
18.14.4 Company Product Benchmarking
18.14.5 Company Recent Developments
18.15 Incyte
18.15.1 Company Snapshot
18.15.2 Company Overview
18.15.3 Company Financial Profile
18.15.4 Company Product Benchmarking
18.15.5 Company Recent Developments
18.16 Regeneron pharmaceuticals Inc.
18.16.1 Company Snapshot
18.16.2 Company Overview
18.16.3 Company Financial Profile
18.16.4 Company Product Benchmarking
18.16.5 Company Recent Developments
18.17 Amgen Inc
18.17.1 Company Snapshot
18.17.2 Company Overview
18.17.3 Company Financial Profile
18.17.4 Company Product Benchmarking
18.17.5 Company Recent Developments
18.18 Bristol Myers Squibb
18.18.1 Company Snapshot
18.18.2 Company Overview
18.18.3 Company Financial Profile
18.18.4 Company Product Benchmarking
18.18.5 Company Recent Developments
18.19 Clovis Oncology
18.19.1 Company Snapshot
18.19.2 Company Overview
18.19.3 Company Financial Profile
18.19.4 Company Product Benchmarking
18.19.5 Company Recent Developments
18.20 Heptares Therapeutics Ltd.
18.20.1 Company Snapshot
18.20.2 Company Overview
18.20.3 Company Financial Profile
18.20.4 Company Product Benchmarking
18.20.5 Company Recent Developments
19 Conclusions & Recommendations
19.1 Concluding Remarks from
19.2 Recommendations for Market Players
19.3 North America to Dominate the Global Checkpoint Inhibitors Market
19.3.1 North America to Hold the Largest Share During Forecast Period
19.3.2 Asia-Pacific Region to Emerge as the Fastest Growing Market
20 Glossary Terms
List of Tables
Table 1. Global Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 2. Global Checkpoint Inhibitors Market Snapshot, 2021 & 2031 (US$billion, CAGR %)
Table 3. Adverse Events Associated with Immune-Checkpoint Blockade
Table 4. Global Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 5. Global Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 6. Global Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 7. Global Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 8. Global Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 9. Global Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 10. Global Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 11. Global Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 12. Global Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 13. Global Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 14. Comparison of PD-L1-PD-L2 ligands
Table 15. Summary of Anti-PD-1/PD-L1 Therapies Approved Indications
Table 16. Summary of Anti-PD-1/PD-L1 Therapies Approved Indications (continued)
Table 17. PD-1/PD-L1 Agents Pipeline Drugs
Table 18. Pembrolizumab Approved Indications
Table 19. Nivolumab Approved Indications
Table 20. Atezolizumab Approved Indications
Table 21. Regeneron’s NSCLC Development Program
Table 22. Global Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 23. Global Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 24. Global Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 25. Global Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 26. Global Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 27. Avelumab Approved Indications
Table 28. Durvalumab Approved Indication
Table 29. Global Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 30. Global Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 31. Global Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 32. Global Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 33. Global Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 34. CTLA-4 Agents in Pipeline
Table 35. Global Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 36. Global Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 37. Global Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 38. Global Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 39. Global Checkpoint Inhibitors for Treating Cancer Market by CTLA-4 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 40. Global Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 41. Global Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 42. Global Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 43. Global Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 44. Global Checkpoint Inhibitors for Treating Cancer Market by Cytokines Targets, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 45. Global Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 46. Global Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 47. Global Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 48. Global Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 49. Global Checkpoint Inhibitors for Treating Cancer Market by Immuno Adjuvants, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 50. Global Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 51. Global Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 52. Global Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 53. Global Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 54. Global Checkpoint Inhibitors for Treating Cancer Market by Immunomodulators, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 55. Global Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 56. Global Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 57. Global Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 58. Global Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 59. Global Checkpoint Inhibitors for Treating Cancer Market by Application, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 60. Global Checkpoint Inhibitors for Treating Cancer Market by Region, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 61. Global Checkpoint Inhibitors for Treating Cancer Market by Region, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 62. Global Checkpoint Inhibitors for Treating Cancer Market by Region, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 63. Global Checkpoint Inhibitors for Treating Cancer Market by Region, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 64. Global Checkpoint Inhibitors for Treating Cancer Market by Region, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 65. North America Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 66. North America Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 67. North America Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 68. North America Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 69. North America Checkpoint Inhibitors for Treating Cancer Market Forecast, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 70. North America Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 71. North America Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (V - Shaped Recovery)
Table 72. North America Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (W - Shaped Recovery)
Table 73. North America Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (U - Shaped Recovery)
Table 74. North America Checkpoint Inhibitors for Treating Cancer Market by Country, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 75. North America Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 76. North America Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (V - Shaped Recovery)
Table 77. North America Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (W - Shaped Recovery)
Table 78. North America Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (U - Shaped Recovery)
Table 79. North America Checkpoint Inhibitors for Treating Cancer Market by Category, 2021-2031 (USD Mn, AGR (%), CAGR(%)) (L - Shaped Recovery)
Table 80. North America Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 81. North America Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 82. North America Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 83. North America Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(U-Shape Recovery)
Table 84. North America Checkpoint Inhibitors for Treating Cancer Market by PD1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(L-Shape Recovery)
Table 85. North America Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))
Table 86. North America Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(V-Shape Recovery)
Table 87. North America Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitors, 2021-2031 (USD Mn, AGR (%), CAGR(%))(W-Shape Recovery)
Table 88. North America Checkpoint Inhibitors for Treating Cancer Market by PD-L1 Inhibitor
